Comments
Hyderabad-based Aurobindo Pharma is looking at inorganic growth opportunities in Eastern Europe and other geographies for deeper market penetration and to secure newer technologies.
Apart from acquisitions, the company is also keen to expand its product portfolio in the US and Western European markets with high-value drugs.
The high-value products that are in the pipeline include oncology, hormones, depot injections, peptides, inhalers, patches and films, vaccines and biosimilars, the company said.
“Our acquisition strategy will be largely around two platforms. One is to penetrate markets deeper and the other to secure newer technologies and platforms. We always maintain that anything that can come across in Eastern Europe will be prioritised,” Aurobindo Pharma’s Managing Director N Govindarajan said in an earnings presentation.
But he was quick to add that there is no pressure on him to do an acquisition to fill any gap as “there is enough opportunities to grow organically“.
Earlier this year, the company announced acquisition of Portugal’s Generis Farmaceutica SA from Magnum Capital Partners for a consideration of €135 million (around ₹969 crore).
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.